COVID-19 vaccination and antirheumatic therapy
Top Cited Papers
Open Access
- 31 July 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (8), 3496-3502
- https://doi.org/10.1093/rheumatology/keab223
Abstract
The coronavirus disease 2019 (COVID-19) vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be among the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pneumococcal and hepatitis B vaccines. The degree to which this will translate to impaired COVID-19 vaccine responses is unclear. Other evidence suggests withholding MTX for 2 weeks post-vaccination may improve responses. Rituximab has been shown to impair humoral responses for 6 months or longer post-administration. Decisions on withholding or interrupting immunosuppressive therapy around COVID-19 vaccination will need to be made prior to the availability of data on specific COVID-19 vaccine response in these patients. With this in mind, this article outlines the existing data on the effect of antirheumatic therapy on vaccine responses in patients with inflammatory arthritis and formulates a possible pragmatic management strategy for COVID-19 vaccination.This publication has 36 references indexed in Scilit:
- Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2012
- Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination studyRheumatology, 2011
- Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center studyArthritis & Rheumatism, 2011
- Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexateAnnals Of The Rheumatic Diseases, 2011
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnnals Of The Rheumatic Diseases, 2010
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Antibody Response to Influenza Immunization in Kidney Transplant Recipients Receiving either Azathioprine or Mycophenolate: A Controlled TrialAmerican Journal of Nephrology, 2008
- Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockersAnnals Of The Rheumatic Diseases, 2006
- Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritisRheumatology, 2005